AstraZeneca has announced a substantial $50 billion investment in U.S. manufacturing by 2030, marking its largest single-site global investment in Virginia. This initiative aims to reinforce domestic supply chains for critical medicines and enhance production capacities amid ongoing regulatory pressures. Simultaneously, the company is advancing its therapeutic pipeline with approvals for key treatments, solidifying its commitment to oncology and rare diseases while addressing challenges like patent expirations and pricing pressures.
“$AZN - ASTRAZENECA'S IMFINZI HAS BEEN APPROVED IN THE EU AS THE FIRST AND ONLY PERIOPERATIVE IMMUNOTHERAPY FOR PATIENTS WITH EARLY GASTRIC AND GASTROESOPHAGEAL CANCERS.”
“Yes. AstraZeneca: Crestor (rosuvastatin statin) + developing AZD0780 (oral PCSK9 inhibitor). Market cap ~$300B (as of Mar 13 2026).”
“Pharmaceutical giants like Johnson & Johnson, AstraZeneca, and Eli Lilly are committing tens of billions of dollars to expand production and research facilities in the United States.”
“Those investments strengthen domestic supply chains for critical medicines and treatments.”
“CVST 3.23x (AstraZeneca dose 1) - Myocarditis up to 6.10x (Moderna dose 2, mRNA) - ADEM 3.78x (Moderna dose 1) - GBS 2.49x (AstraZeneca dose 1).”
“GBS 2.49x (AstraZeneca dose 1). It confirms known signals, not overall crisis or ineffectiveness.”
“Eine Frau will 150.000 Euro Schadenersatz von der Firma AstraZeneca, weil sie seit der Corona-Impfung taub ist. Zwei Gerichte lehnen ihre Klage ab. Doch nun gibt ihr der Bundesgerichtshof teilweise recht.”
“The main companies profiting from flu vaccines are ... AstraZeneca (FluMist). They produce and sell ~150M+ doses annually in the US alone (projected for 2025-26 season), plus globally, to governments, pharmacies, and providers—generating billions in revenue as part of their broader portfolios.”
“The 2024 GVDN study (Vaccine journal) of 99M people confirmed known rare signals using observed-vs-expected rates: myocarditis/pericarditis mainly after mRNA doses... No 'crisis' or ineffectiveness found—study supports overall safety profile.”
“Soliris® daripada AstraZeneca diluluskan di Malaysia untuk rawatan penyakit autoimun neurologi yang jarang berlaku dan penyakit darah yang teruk”
“TTS is mainly tied to adenovirus-vector vaccines (J&J, AstraZeneca). COVID infection itself raises clotting/ITP risks far more.”
“Ações assinadas na pandemia incluem MPs principais para vacinas: R$1,9 bi (ago/2020, Oxford/AstraZeneca), R$20 bi (dez/2020, aquisição geral), R$5,5 bi (mai/2021, produção/distribuição).”
